Drug Search Results
More Filters [+]

Ivaltinostat

Alternative Names: Ivaltinostat, cg-200745, cg200745, cg 200745
Latest Update: 2024-05-29
Latest Update Note: News Article

Product Description

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28134290/)

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CrystalGenomics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ivaltinostat

Countries in Clinic: Korea, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Adenocarcinoma|Myelodysplastic Syndrome|Pancreatic Cancer|Preleukemia

Phase 1: Healthy Volunteers|Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CG-745-2-08

P2

Recruiting

Pancreatic Cancer|Adenocarcinoma

2025-02-01

CG200745-1-02

P1

Active, not recruiting

Oncology Hematological Unspecified|Oncology Solid Tumor Unspecified|Healthy Volunteers

2023-12-01

CG200745-2-02

P2

Active, not recruiting

Preleukemia|Myelodysplastic Syndrome

2022-12-01

24%

CG200745-2-02

P2

Active, not recruiting

Preleukemia|Myelodysplastic Syndrome

2022-12-01

24%

CG200745-2-02

P2

Active, not recruiting

Preleukemia|Myelodysplastic Syndrome

2022-12-01

24%

Recent News Events